Skip to main content
SpringerLink
Log in

Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score

  • Colorectal Cancer
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Background

Curative treatment of pseudomyxoma peritonei (PMP) is complete cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC).

Objective

The aim of this study was to build and evaluate a preoperative imaging score to predict resectability.

Patients and methods

Between 2007 and 2014, all PMP patients in two tertiary reference centers who underwent laparotomy with intent to undergo CRS and HIPEC were included in this study retrospectively. Thickness of tumor burden was measured on preoperative multidetector-row computed tomography (MDCT) by two radiologists blinded to surgical results in five predetermined areas. Patients were divided into two cohorts with the same resectability rate (building and validation). The performances of the scores were assessed using receiver operating characteristic (ROC) curve analyses.

Results

Overall, 126 patients were included, with compete CRS being achieved in 91/126 patients (72.2%). Two cohorts of 63 patients matched by age, sex, burden of disease, resectability rate, and pathological grade were constituted. The MDCT score was the sum of the five measures, and was higher in unresectable disease [median 46.2 mm (range 27.9–74.6) vs. 0.0 mm (range 0.0–14.0), p < 0.001]. Area under the ROC curve was 0.863 (range 0.727–0.968) and 0.801 (range 0.676–0.914) in the building and validation cohorts, respectively. A threshold of 28 mm yielded a sensitivity, specificity, positive predictive and negative predictive value of 94, 81, 81 and 94% in the building cohort, and 80, 68, 59 and 85% in the validation cohort, respectively. Using our score, overall and disease-free survival were increased in the group classified as resectable.

Conclusion

A simple preoperative MDCT score measuring tumor burden in the perihepatic region is able to predict resectability and survival of PMP patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Smeenk RM, Verwaal VJ, Zoetmulder FA. Pseudomyxoma peritonei. Cancer Treat Rev. 2007;33(2):138–45.

    Article  CAS  PubMed  Google Scholar 

  2. Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ. Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline (low malignant potential) tumors of the ovary. Anat Pathol. 1997;2:197–26.

    CAS  PubMed  Google Scholar 

  3. Slim K, Blay JY, Brouquet A, et al. Digestive oncology: surgical practices [in French]. J Chir (Paris). 2009;146(Suppl 2):S11–S80.

    Google Scholar 

  4. Moran BJ, Cecil TD. The etiology, clinical presentation, and management of pseudomyxoma peritonei. Surg Oncol Clin N Am. 2003;12(3):585–603.

    Article  PubMed  Google Scholar 

  5. Elias D, Gilly F, Quenet F, et al. Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J Surg Oncol. 2010;36(5):456–62.

    Article  CAS  PubMed  Google Scholar 

  6. Passot G, Vaudoyer D, Villeneuve L, et al. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol. 2016;113(7):796–803.

    Article  PubMed  Google Scholar 

  7. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.

    Article  PubMed  Google Scholar 

  8. Baratti D, Kusamura S, Milione M, et al. Pseudomyxoma peritonei of extra-appendiceal origin: a comparative study. Ann Surg Oncol. 2016;23(13):4222–30.

    Article  PubMed  Google Scholar 

  9. Ansari N, Chandrakumaran K, Dayal S, Mohamed F, Cecil TD, Moran BJ. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in 1000 patients with perforated appendiceal epithelial tumours. Eur J Surg Oncol. 2016;42(7):1035–41.

    Article  CAS  PubMed  Google Scholar 

  10. Loungnarath R, Causeret S, Brigand C, Gilly FN, Glehen O. Pseudomyxoma peritonei: new concept and new therapeutic approach [in French]. Ann Chir. 2005;130(2):63–69.

    Article  CAS  PubMed  Google Scholar 

  11. Delhorme JB, Elias D, Varatharajah S, et al. Can a Benefit be Expected from Surgical Debulking of Unresectable Pseudomyxoma Peritonei? Ann Surg Oncol. 2016;23(5):1618–24.

    Article  PubMed  Google Scholar 

  12. Sulkin TV, O’Neill H, Amin AI, Moran B. CT in pseudomyxoma peritonei: a review of 17 cases. Clin Radiol. 2002;57(7):608–13.

    Article  CAS  PubMed  Google Scholar 

  13. Diop AD, Fontarensky M, Montoriol PF, Da Ines D. CT imaging of peritoneal carcinomatosis and its mimics. Diagn Interv Imaging. 2014;95(9):861–72.

    Article  CAS  PubMed  Google Scholar 

  14. Menassel B, Duclos A, Passot G, et al. Preoperative CT and MRI prediction of non-resectability in patients treated for pseudomyxoma peritonei from mucinous appendiceal neoplasms. Eur J Surg Oncol. 2016;42(4):558–66.

    Article  CAS  PubMed  Google Scholar 

  15. Chua TC, Al-Zahrani A, Saxena A, et al. Determining the association between preoperative computed tomography findings and postoperative outcomes after cytoreductive surgery and perioperative intraperitoneal chemotherapy for pseudomyxoma peritonei. Ann Surg Oncol. 2011;18(6):1582–89.

    Article  PubMed  Google Scholar 

  16. Sugarbaker PH. Peritonectomy procedures. Ann Surg. 1995;221(1):29–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Sugarbaker PH. Pseudomyxoma peritonei. A cancer whose biology is characterized by a redistribution phenomenon. Ann Surg. 1994;219(2):109–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.

    Article  CAS  PubMed  Google Scholar 

  19. Benhaim L, Honore C, Goere D, Delhorme JB, Elias D. Huge pseudomyxoma peritonei: Surgical strategies and procedures to employ to optimize the rate of complete cytoreductive surgery. Eur J Surg Oncol. 2016;42(4):552–57.

    Article  CAS  PubMed  Google Scholar 

  20. Dohan A, Hoeffel C, Soyer P, et al. Evaluation of the peritoneal carcinomatosis index with CT and MRI. Br J Surg. 2017;104(9):1244–49.

    Article  CAS  PubMed  Google Scholar 

  21. Jacquet P, Jelinek JS, Chang D, Koslowe P, Sugarbaker PH. Abdominal computed tomographic scan in the selection of patients with mucinous peritoneal carcinomatosis for cytoreductive surgery. J Am Coll Surg. 1995;181(6):530–38.

    CAS  PubMed  Google Scholar 

  22. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: a consensus statement. Society of Surgical Oncology. Ann Surg Oncol. 2007;14(1):128–33.

    Article  CAS  PubMed  Google Scholar 

  23. Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings–a feasibility study. AJR Am J Roentgenol. 2009;193(2):461–70.

    Article  PubMed  Google Scholar 

  24. Klumpp B, Aschoff P, Schwenzer N, et al. Correlation of preoperative magnetic resonance imaging of peritoneal carcinomatosis and clinical outcome after peritonectomy and HIPEC after 3 years of follow-up: preliminary results. Cancer Imaging. 2013;13(4):540–47.

    Article  CAS  PubMed  Google Scholar 

  25. Passot G, Glehen O, Pellet O, et al. Pseudomyxoma peritonei: role of 18F-FDG PET in preoperative evaluation of pathological grade and potential for complete cytoreduction. Eur J Surg Oncol. 2010;36(3):315–23.

    Article  CAS  PubMed  Google Scholar 

  26. Dubreuil J, Giammarile F, Rousset P, et al. FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. Eur J Nucl Med Mol Imaging. 2016;43(9):1630–37.

    Article  PubMed  Google Scholar 

  27. Dohan A, Barral M, Eveno C, et al. Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery. Eur J Surg Oncol. 2017;43(10):1932–38.

    Article  CAS  PubMed  Google Scholar 

  28. Valle M, Garofalo A. Laparoscopic staging of peritoneal surface malignancies. Eur J Surg Oncol. 2006;32(6):625–27.

    Article  PubMed  Google Scholar 

  29. Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D. The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31(5):540–43.

    Article  CAS  PubMed  Google Scholar 

  30. Najah H, Lo Dico R, Grienay M, Dohan A, Dray X, Pocard M. Single-incision flexible endoscopy (SIFE) for detection and staging of peritoneal carcinomatosis. Surg Endosc. 2016;30(9):3808–815.

    Article  PubMed  Google Scholar 

  31. Ladjici Y, Dray X, Marteau P, Valleur P, Pocard M. Flexible versus rigid single-port peritoneoscopy: a randomized controlled trial in a live porcine model followed by initial experience in human cadavers. Surg Endosc. 2012;26(9):2651–57.

    Article  CAS  PubMed  Google Scholar 

  32. Najah H, Lo Dico R, Dohan A, Marry L, Eveno C, Pocard M. A feasibility study of the use of computed virtual chromoendoscopy for laparoscopic evaluation of peritoneal metastases. Surg Endosc. 2017;31(2):743–51.

    Article  PubMed  Google Scholar 

  33. Pocard M, Eveno C, Valleur P. Regarding “two steps procedure for pseudomyxoma”. Ann Surg Oncol. 2011;18(1):282–83; author reply 284–85.

  34. Dayal S, Taflampas P, Riss S, et al. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved. Dis Colon Rectum. 2013;56(12):1366–72.

    Article  PubMed  Google Scholar 

Download references

Disclosures

Morgane Bouquot, Anthony Dohan, Etienne Gayat, Maxime Barat, Olivier Glehen, Marc Pocard, Pascal Rousset, and Clarisse Eveno have no financial or other personal conflicts of interest to declare.

Author information

Authors and Affiliations

  1. Department of Digestive and Oncological Surgery, Hôpital Lariboisière-AP-HP, Paris, France

    Morgane Bouquot MD

  2. Department of Body and Interventional Imaging, Hôpital Cochin-AP-HP, Université Sorbonne Paris Cité – Paris Descartes, Paris, France

    Anthony Dohan MD, PhD & Maxime Barat MD

  3. Department of Anesthesiology and Critical Care Medicine, Hôpital Lariboisière-AP-HP, Université Sorbonne Paris Cité – Paris Diderot, Paris, France

    Etienne Gayat MD, PhD

  4. Department of Digestive and Oncologic Surgery, Centre Hospitalier Lyon Sud – HCL, Lyon 1 University Pierre-Bénite, Lyon, France

    Olivier Glehen MD, PhD

  5. Department of Digestive and Oncological Surgery, Hôpital Lariboisière-AP-HP, Sorbonne Paris Cité – Paris Diderot, Paris, France

    Marc Pocard MD, PhD & Clarisse Eveno MD, PhD

  6. Department of Radiology, Centre Hospitalier Lyon Sud – HCL, Lyon 1 University Pierre-Bénite, Lyon, France

    Pascal Rousset MD, PhD

  7. INSERM U 965, Paris, France

    Morgane Bouquot MD, Anthony Dohan MD, PhD, Etienne Gayat MD, PhD, Marc Pocard MD, PhD & Clarisse Eveno MD, PhD

Authors
  1. Morgane Bouquot MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anthony Dohan MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Etienne Gayat MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maxime Barat MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Olivier Glehen MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc Pocard MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pascal Rousset MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Clarisse Eveno MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Morgane Bouquot contributed to the acquisition of data, writing of the manuscript and analysis of data. Anthony Dohan, Maxime Barat and Clarisse Eveno contributed to development of the methodology, interpretation of data, and conception, design, and review of the manuscript. Etienne Gayat contributed to development of the methodology, analysis and interpretation of data, and writing and review of the manuscript. Olivier Glehen and Marc Pocard contributed to revision of the manuscript and study supervision. Pascal Rousset contributed to acquisition and analysis of data, and review of the manuscript.

Corresponding author

Correspondence to Clarisse Eveno MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bouquot, M., Dohan, A., Gayat, E. et al. Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score. Ann Surg Oncol 25, 694–701 (2018). https://doi.org/10.1245/s10434-017-6275-7

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-017-6275-7

Keywords

Search

Navigation